Back to Archived Journals » Current Biomarker Findings » Volume 4

Predicting efficacy of sunitinib in metastatic renal cell carcinoma

Authors Ganini C, Porta C

Received 11 October 2013

Accepted for publication 24 December 2013

Published 29 May 2014 Volume 2014:4 Pages 43—52

DOI https://doi.org/10.2147/CBF.S39103

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Carlo Ganini,1,* Camillo Porta1,2,*

1Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo University Hospital Foundation, 2Italian Group of Nephro-Oncology/Gruppo Italiano di Oncologia Nefrologica, Pavia, Italy

*Both authors contributed equally to this paper

Abstract: Renal cell carcinoma accounts for 3% of all solid neoplasms in adults. Once poorly treated due to its poorly understood pathogenesis, the discovery of the role played by the vascular endothelial growth factor pathway in renal cell carcinoma has led to development of a number of targeted therapies that have impacted on the natural history of the disease. One of the problems related to this apparent abundance of therapies is choice of a drug tailored to the individual patient. Of all the drugs available, sunitinib accounts for more than 50% of first-line therapy. Defining which group of patients will benefit from sunitinib using a predictive biomarker would be of great help for its clinical activity. Local efforts have identified biomarkers that are potentially predictive of the efficacy of sunitinib in patients with metastatic renal cancer, being either clinical (hypertension), cellular (such as circulating endothelial cells, circulating tumoral cells), or molecular (cytokines such as vascular endothelial growth factor, hepatocyte growth factor/scatter factor), but there is a desperate need to increase the numbers of patients in the studies being conducted to provide more valid and reproducible data of use in clinical decision-making regarding therapy.

Keywords: kidney cancer, sunitinib, predictive biomarker, target therapy, tyrosine kinase inhibitor


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]